<DOC>
	<DOCNO>NCT00428220</DOCNO>
	<brief_summary>This study use sunitinib patient end treatment previous sunitinib malate protocol continue receive sunitinib . The patient must enrol one follow study : A6181030 , A6181064 , A6181078 , A6181087 , A6181094 , A6181107 , A6181108 , A6181110 , A6181111 , A6181112 , A6181113 , A6181120 , A6181126 A6181170 . Other Pfizer sponsor sunitinib study may include future .</brief_summary>
	<brief_title>A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Carcinoma , Islet Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Must end treatment one follow sunitinib study : A6181030 , A6181064 , A6181078 , A6181087 , A6181094 , A6181107 , A6181108 , A6181110 , A6181111 , A6181112 , A6181113 , A6181120 , A6181126 A6181170 . Other Pfizer sponsor sunitinib study may include future . See inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Potentially tumor type future</keyword>
</DOC>